By Lisa Kerner
Charlotte, N.C., Oct. 9 - AGI Dermatics closed a $5.5 million round of series A private equity financing.
Proceeds will accelerate the growth of the company's Remergent brand for hyperpigmentation and extend clinical studies of Dimericine, the "morning after" topical lotion for prevention of skin cancer.
Trevi Health Ventures led the round, with participation from WHI Group and other private investors.
Andrew Fink, managing director of Trevi, and Steven Kaye, an investor in Trevi, will join AGI's board of directors.
AGI, based in Freeport, N.Y., specializes in the commercial applications of DNA repair, photobiology and skin delivery systems.
| Issuer: | AGI Dermatics
|
| Issue | Series A private equity financing
|
| Amount: | $5.5 million
|
| Investors: | Trevi Health Ventures led the round, with participation from WHI Group and other private investors
|
| Announcement date: | Oct. 9
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
